Bank of America Raises Hims & Hers Health (NYSE:HIMS) Price Target to $26.00

Hims & Hers Health (NYSE:HIMS) had its price target hoisted by Bank of America from $22.00 to $26.00 in a research report released on Thursday, Benzinga reports. Bank of America currently has a buy rating on the stock.

HIMS has been the topic of several other research reports. Truist Financial lifted their price target on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a report on Tuesday, February 27th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a buy rating and a $20.00 price target on the stock. Imperial Capital raised shares of Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 price target on the stock in a report on Wednesday, February 28th. Leerink Partnrs reaffirmed a market perform rating on shares of Hims & Hers Health in a report on Monday, February 26th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a buy rating in a report on Wednesday, May 22nd. Seven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $16.43.

Hims & Hers Health Trading Down 2.5 %

HIMS opened at $23.75 on Thursday. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -2,375.00 and a beta of 1.08. The company’s 50 day moving average is $15.78 and its 200 day moving average is $12.56. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $24.56.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) earnings per share. As a group, analysts predict that Hims & Hers Health will post 0.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 50,361 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total value of $822,898.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 50,361 shares of Hims & Hers Health stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 9,912 shares of Hims & Hers Health stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $15.82, for a total transaction of $156,807.84. Following the transaction, the chief financial officer now directly owns 168,627 shares of the company’s stock, valued at $2,667,679.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 951,004 shares of company stock worth $16,188,821. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Forerunner Ventures Management LLC bought a new position in Hims & Hers Health in the fourth quarter worth about $86,836,000. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. M&G Plc acquired a new position in shares of Hims & Hers Health during the first quarter valued at about $8,232,000. Vanguard Group Inc. increased its holdings in shares of Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Hims & Hers Health by 39.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock valued at $8,006,000 after acquiring an additional 357,590 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.